Burton Karen L sold $1.5M of STE

Burton Karen L (Sr. Vice Pres., CFO) sold 5,880 shares of STERIS plc (STE) at $255.62 ($1.50M total) on 2026-11-11.

Original reporting
SEC EDGAR · Burton Karen L
Published Nov 12, 2026, 9:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Bearish
medium confidence
Mentioned
$STE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STEBearishLow
01

Why it matters

The CFO's sale may be interpreted by investors as a slight bearish cue, though the amount is relatively small.

02

Market read

Provides a modest, new data point for traders monitoring insider activity.

03

What to watch

No 10b5-1 plan was used, indicating the sale was discretionary.

Relevance 6/10Novelty 4/10Timing: post-market today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$STEBearishMedium confidence
Context

CFO Burton Karen L sold 5,880 shares of Steris plc for $1.5M in a Form 4 filing.

Expected impact

likely modest downside as market prices in the insider sell.

Evidence & confidence

The sale size is modest but involves a senior executive; traders may view it as a weak bearish signal.

Market effects

Minimal impact on the healthcare equipment sector.

U.S. market only; no broader regional effect.

Low relevance globally.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Steris plc

    Medical device and equipment manufacturer.

  • Burton Karen L

    Senior Vice President, CFO of Steris plc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STEMedAI 8/10

STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland and a wholly-owned subsidiary of STERIS plc, a public…

STERIS plc (STE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 9, 2026, STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland (the “Issuer”) and a wholly-owned subsidiary of STERIS plc, a public limited company incorporated under the laws of Ireland (the “C

$STEMed

What STERIS (STE) Said on Its Q2 Earnings Call

STERIS (STE) reported Q2 adjusted EBIT margin up 150 bps to 24.6%, with EPS growth of 13% excluding refunds. Life Sciences revenue rose 18%, leading to an increased full-year growth forecast of 9-10%. AST segment revenue grew 5%, but its forecast was lowered to 6-7%. The company announced a $45M restructuring plan and expects its Xodus Medical acquisition to boost revenue and margins.

$STEMed

Steris PLC (STE) (Q2 2027) Earnings Call Highlights: Revenue Climbs 9%

STERIS PLC reported Q2 2027 revenue up 9%, but EBIT margins declined in both Healthcare and AST segments due to inflation and other factors. AST revenue growth guidance was lowered. Free cash flow decreased. A $45M restructuring plan was announced. CEO Dan Carestio discussed growth opportunities, including the Xodus Medical acquisition, and addressed margin pressures and market dynamics.

$STEHighAI 8/10

STERIS (STE) Q2 2027 Earnings Call Transcript

STERIS (STE) reported Q2 2027 earnings with adjusted EBIT margin at 24.6%, up 150 bps YoY. Adjusted EPS grew 19% to $2.94. Revenue grew 7-8%, with Healthcare up 7%, AST up 5%, and Life Sciences up 18%. The company announced plans to acquire Xodus Medical. Full-year EPS outlook raised to $11.35-$11.55. Free cash flow was $492.5M for H1 2027.

$CATMedAI 8/10

Caterpillar's $1B Sanford Plant Fuels Raleigh-Durham Growth

Caterpillar plans to invest $1B in a North Carolina plant, expanding manufacturing capacity. The project is part of a broader industrial surge in Raleigh-Durham, with increased leasing activity and construction. Other companies, including AbbVie, Siemens, and Forge Nano, are also investing in the region. Research Triangle Park is diversifying with mixed-use and residential developments.